{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-029968","form_type":"8-K","ticker":"GANX","cik":"0001819411","company_name":"Gain Therapeutics, Inc.","filed_at":"2026-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.323194+00:00","generated_at":"2026-05-15T09:55:24.136224+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Gain Therapeutics presents Phase 1b data showing stable MDS-UPDRS and biomarker improvements for GT-02287 at AD/PD 2026","bullets":["Phase 1b: 19 completed Part 1, 16 entered extension; DMC approved continuation without changes.","MDS-UPDRS scores stable over 150 days; high GluSph group showed 6.7-point difference vs low group.","DDC decreased after 90 days in high GluSph baseline group, supporting disease-modifying potential.","Preclinical data for novel GCase modulator GT-04686 presented, ready for IND-enabling studies.","Extension study expected to complete September 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-029968","json":"https://secwatch.observer/filing/0001104659-26-029968.json","markdown":"https://secwatch.observer/filing/0001104659-26-029968.md","text":"https://secwatch.observer/filing/0001104659-26-029968.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819411/000110465926029968/0001104659-26-029968-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819411/000110465926029968/tm269191d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:55:24.136224+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}